BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/22/2026 5:32:18 AM | Browse: 1 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Icaritin targeting epithelial-mesenchymal transition in colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Na-Qi Sun, Han-Xiao Zhang and Sai-Jun Mo |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Foundation of Henan Educational Committee |
No. 26A310017 |
| College Student Innovation and Entrepreneurship Competitions |
No. 202510459174 and No. 2025cxcy639 |
|
| Corresponding Author |
Sai-Jun Mo, Associate Professor, PhD, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, No. 100 Science Avenue, Zhongyuan District, Zhengzhou 450001, Henan Province, China. sjmo@zzu.edu.cn |
| Key Words |
Icaritin; Colorectal cancer; Metastasis; Epithelial-mesenchymal transition; Wnt/β-catenin signaling pathway |
| Core Tip |
This commentary evaluates the study by Li et al, which suggests that icaritin inhibits colorectal cancer metastasis by reversing epithelial-mesenchymal transition and suppressing Wnt/β-catenin signaling. Although the findings are promising, changes in protein expression alone do not adequately confirm modulation of the pathway. Further research is necessary, including target localization studies and rescue experiments utilizing pathway activators, inhibitors, or gene modulation, to establish the dependence on Wnt/β-catenin signaling. For clinical translation, it is essential to validate targets, develop improved formulations to address issues of poor solubility and bioavailability, and conduct clinical trials to verify both efficacy and safety. Addressing these gaps will be crucial in establishing icaritin as a viable therapeutic strategy for the management of colorectal cancer. |
| Citation |
Sun NQ, Zhang HX, Mo SJ. Letter to the Editor: Icaritin targeting epithelial-mesenchymal transition in colorectal cancer. World J Gastrointest Oncol 2026; In press |
 |
Received |
|
2026-02-10 00:56 |
 |
Peer-Review Started |
|
2026-02-10 01:00 |
 |
First Decision by Editorial Office Director |
|
2026-02-26 07:17 |
 |
Return for Revision |
|
2026-02-26 07:17 |
 |
Revised |
|
2026-03-06 15:48 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-04-22 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-04-22 05:32 |
 |
Articles in Press |
|
2026-04-22 05:32 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345